Overview

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

Status:
Terminated
Trial end date:
2018-05-05
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2a study investigating the safety and efficacy of Sym004, an investigational medicinal product (IMP), in combination with FOLFIRI (chemotherapy) when administered every second week (Q2W).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Symphogen A/S
Treatments:
Camptothecin
Fluorouracil
Folic Acid
Irinotecan
Leucovorin
Levoleucovorin